ライフサイエンスコーパス: malaise

1 ebo group, and included headache, fever, and malaise).

2 /soreness, chills, arthralgia, anorexia, and malaise).

3 ng properties of LiCl or by a lesion-induced malaise.

4 ors, arthralgias, myalgias, headache, and/or malaise.

5 l tastant and toxin-induced gastrointestinal malaise.

6 s, after having experienced gastrointestinal malaise.

7 t presenting with complaints of headache and malaise.

8 also a harbinger of cellular and organismal malaise.

9 ssociated with grade I flu-like symptoms and malaise.

10 average meal size and independent of nausea/malaise.

11 ic effect of NAc core GLP-1 is not caused by malaise.

12 he taste that was previously associated with malaise.

13 he taste that was previously associated with malaise.

14 components of anxiety, stress, and visceral malaise.

15 avoidance of tastes associated with visceral malaise.

16 toxicity, nausea or vomiting, and fatigue or malaise.

17 nia, hyponatremia, hypokalemia, fatigue, and malaise.

18 lulike" illness associated with myalgias and malaise.

19 body weight gain without causing CNS-related malaise.

20 did not confirm that SEB challenge promotes malaise.

21 nes were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%) the most frequent ad

22 fatigue (29 [43%]), headache (26 [39%]), and malaise (15 [22%]).

23 geal signs but less frequently complained of malaise; (2) had larger EM skin lesions despite similar

24 eveloped low-grade fever, chills, cough, and malaise 3 days prior to admission, and then progressive

25 (59.7%), headache (46.8%), fatigue (44.2%), malaise (39%), paresthesias (32.5%), peripheral facial p

26 ents treated with vorinostat were fatigue or malaise (51 [16%] patients in the vorinostat group vs 25

27 cific manifestations, including fever (96%), malaise (88%), myalgia (57%), cough (25%), and dizziness

28 ed to this hospital because of confusion and malaise after resection of a papillary urothelial cancer

29 One patient had myalgias and malaise after the first infliximab infusion and flu-like

30 xicity, including fever, chills, nausea, and malaise, although no patient had grade 3 or 4 toxicity.

31 ent developed new onset of nausea, vomiting, malaise and deep jaundice.

32 ttent, vague, and nonspecific, largely being malaise and easy fatiguability.

33 ic mechanism through which cisplatin-induced malaise and energy balance dysregulation are mediated.

34 Systemic inflammation causes malaise and general feelings of discomfort.

35 n VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic sym

36 he presentation, in both instances, was with malaise and lethargy.

37 episodes, which in humans results in severe malaise and may lead to death.

38 Systemic reactions included mild to moderate malaise and myalgia.

39 -term emotional memories as assessed by odor-malaise and tone-shock associations.

40 V) developed signs of acute viral infection (malaise and weight loss) and had MCMV loads that were re

41 patient presented with shortness of breath, malaise, and cough that had developed 3 days prior to ad

42 ted as an elevation in liver function tests, malaise, and edema.

43 Constitutional symptoms (fever, malaise, and fatigue) and asymptomatic hyperbilirubinemi

44 ost common systemic reactions were headache, malaise, and myalgia.

45 acne-like skin rash, leukopenia, fatigue and malaise, and nausea and vomiting.

46 The home environment, parental malaise, and the child's own IQ may have a role in expla

47 for the full expression of cisplatin-induced malaise, anorexia, and body weight loss.

48 entations with enlarged lymph nodes, fevers, malaise, anorexia, weight loss, hypoalbuminemia, and gas

49 tration, no effects of galantamine on nausea/malaise as measured by pica were noted.

50 (PBN) neurons prevents lethargy, anxiety and malaise associated with cancer.

51 s (CB) have been used to combat the visceral malaise associated with chronic disease, although the me

52 ls in the brainstem is a likely cause of the malaise associated with these disorders.

53 ement of the Environment scores and parental malaise attenuated associations with the mother's IQ but

54 sing a small number of RBC units for general malaise attributed to anaemia, a practice that appears t

55 using small numbers of RBC units for general malaise attributed to anaemia, a practice which appears

56 a neuromodulator in the hindbrain to produce malaise by potentiating visceral afferent signaling at t

57 een associated with lithium chloride-induced malaise, c-Fos protein expression increased dramatically

58 erent families cause a syndrome of fever and malaise, 'capillary leak' with loss of plasma volume, an

59 We propose that visceral malaise contributes to the stressful and anxiogenic effe

60 the first dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis.

61 nfusion, there was resolution of fatigue and malaise, disappearance of fever, and regression of lymph

62 e symptoms (such as fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before rand

63 s included anemia (33%), infection (24%) and malaise/fatigue (14%).

64 3 or 4 treatment-related adverse events were malaise/fatigue and diarrhea, occurring in 17% and 7% of

65 es were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vomiting, alopecia, thrombocytop

66 her common but mild adverse effects included malaise/fatigue, peripheral edema, and hyperglycemia.

67 Diarrhea, nausea, malaise/fatigue, vomiting, and mucositis were the most c

68 for many symptoms such as sleep disorder and malaise/feebleness was also significantly improved after

69 n, visual loss, and constitutional symptoms (malaise, fever, weight loss, loss of appetite).

70 ffectiveness of cannabinoids in blocking the malaise generated by TNF-releasing disease processes by

71 loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and one had severe ch

72 All patients had fever, malaise, headache, and lymphopenia; three had thrombocyt

73 fluconazole discontinued treatment owing to malaise, headache, and moderate dizziness (Common Termin

74 ing fever in 23 (82%), headache in 14 (50%), malaise in 13 (46%), dizziness in nine (32%), myalgia in

75 ated distinct mechanisms for post-exertional malaise in CFS and START and STOPP phenotypes of GWI.

76 Marek's disease virus (MDV) causes a general malaise in chickens that is mostly characterized by the

77 -induced pica (a proxy for nausea/behavioral malaise in nonvomiting laboratory rodents) and that CeA

78 tested in rats with 2 measures sensitive to malaise, increased kaolin consumption (pica behavior) an

79 derstood and are investigated here using the malaise-inducing agent lithium chloride (LiCl).

80 NPY's orexigenic and malaise-inducing properties were tested in rats with 2 m

81 s that exogenous NPY has both orexigenic and malaise-inducing properties.

82 by AgRP neuron ablation or gastrointestinal malaise inhibits feeding.

83 e general health questionnaire (GHQ) and the malaise inventory (divided into psychological and somati

84 or the psychological symptom subscale of the malaise inventory (regression coefficient -0.024, 95 per

85 gh psychological and somatic symptoms on the malaise inventory.

86 ured using the Psychological subscale of the Malaise Inventory; frequency of physical activity, by qu

87 including fever (>/=38.5 degrees C), rigors, malaise, lethargy, flank pain, hematuria, suprapubic dis

88 ), nausea (50%), vomiting (34%), and fatigue/malaise/lethargy (24%).

89 e formation of a conditioned taste aversion (malaise-like behavior).

90 The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and

91 ia and constitutional symptoms consisting of malaise, myalgias, and anorexia were the dose-limiting t

92 His illness onset included malaise, myalgias, and low-grade fever.

93 nted with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash

94 ent refusal (n=2); and arthralgia, rash, and malaise (n=1 each).

95 %] of 171), headache (12 [7.0%] of 171), and malaise (nine [5.3%] of 171) in patients receiving ledip

96 g at a 10-fold lower dose was neither due to malaise nor motoric impairment.

97 ucleus accumbens-without inducing concurrent malaise or locomotor impairment.

98 ctions in meal size and is not due to nausea/malaise or prolonged suppression of locomotor activity.

99 These effects did not appear to be due to malaise or suppression of motor behavior because drug-tr

100 these data is that NPY produces some form of malaise or visceral illness.

101 de 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any grade, 9% with grade

102 Refractory giardiasis was associated with malaise (P = .007) and anorexia (P = .02), with previous

103 (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metallic taste,

104 ntinuities reveal how aspects of psychiatric malaise run deeper than our species' history.

105 tioned stimulus [CS]) with the experience of malaise (such as that induced by LiCl; unconditioned sti

106 Post-exertional malaise suggests exercise alters central nervous system

107 reinforcer selective and not due to adverse malaise symptoms such as nausea.

108 ural effects of OEA may result from visceral malaise via the activation of TRPV1.

109 Fatigue or malaise was the most common systemic adverse event, repo

110 n, he developed recurrent rashes with fever, malaise, weakness, hepatitis, weight loss, and renal fai

111 eiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide.

112 cantly decreased food intake without causing malaise, whereas intracerebroventricular infusion of apo

113 ns and symptoms such as headache, fever, and malaise, which can progress to chronic airway inflammati